{"denoms":[{"counts":[{"groupId":"BG000","value":"859"},{"groupId":"BG001","value":"859"},{"groupId":"BG002","value":"1718"}],"units":"Participants"}],"groups":[{"description":"Participants randomized to receive zoledronic acid 4 mg intravenously plus placebo to denosumab subcutaneously once every 4 weeks in the double-blind treatment phase.","id":"BG000","title":"Zoledronic Acid"},{"description":"Participants randomized to receive denosumab 120 mg subcutaneously plus placebo to zoledronic acid intravenously once every 4 weeks in the double-blind treatment phase.","id":"BG001","title":"Denosumab"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.5","value":"63.3"},{"groupId":"BG001","spread":"10.6","value":"63.5"},{"groupId":"BG002","spread":"10.6","value":"63.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"464"},{"groupId":"BG001","value":"472"},{"groupId":"BG002","value":"936"}],"title":"< 65 years"},{"measurements":[{"groupId":"BG000","value":"395"},{"groupId":"BG001","value":"387"},{"groupId":"BG002","value":"782"}],"title":"≥ 65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"386"},{"groupId":"BG001","value":"397"},{"groupId":"BG002","value":"783"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"473"},{"groupId":"BG001","value":"462"},{"groupId":"BG002","value":"935"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"70"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"819"},{"groupId":"BG001","value":"823"},{"groupId":"BG002","value":"1642"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"6"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"699"},{"groupId":"BG001","value":"711"},{"groupId":"BG002","value":"1410"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"101"},{"groupId":"BG001","value":"107"},{"groupId":"BG002","value":"208"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"65"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"29"}],"title":"Other"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Multiracial"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Missing"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"259"},{"groupId":"BG001","value":"263"},{"groupId":"BG002","value":"522"}],"title":"0 (Fully active)"},{"measurements":[{"groupId":"BG000","value":"413"},{"groupId":"BG001","value":"400"},{"groupId":"BG002","value":"813"}],"title":"1 (Restricted but ambulatory)"},{"measurements":[{"groupId":"BG000","value":"187"},{"groupId":"BG001","value":"196"},{"groupId":"BG002","value":"383"}],"title":"2 (Ambulatory but unable to work)"}]}],"description":"A scale to assess a patient's disease status. 0 = Fully active, able to carry out all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity, ambulatory and able to carry out work of a light nature; 2 = Ambulatory and capable of all self-care, unable to carry out any work activities. Up and about \\> 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair \\> 50% of waking hours; 4 = Completely disabled, confined to bed or chair; 5 = Dead.","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"577"},{"groupId":"BG001","value":"567"},{"groupId":"BG002","value":"1144"}]}],"title":"Any Skeletal Related Event"},{"categories":[{"measurements":[{"groupId":"BG000","value":"463"},{"groupId":"BG001","value":"479"},{"groupId":"BG002","value":"942"}]}],"title":"Pathological fracture"},{"categories":[{"measurements":[{"groupId":"BG000","value":"115"},{"groupId":"BG001","value":"92"},{"groupId":"BG002","value":"207"}]}],"title":"Spinal cord compression"},{"categories":[{"measurements":[{"groupId":"BG000","value":"139"},{"groupId":"BG001","value":"118"},{"groupId":"BG002","value":"257"}]}],"title":"Radiation therapy to bone"},{"categories":[{"measurements":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"142"},{"groupId":"BG002","value":"286"}]}],"title":"Surgery to bone"}],"paramType":"NUMBER","title":"Skeletal Related Event History","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"465"},{"groupId":"BG001","value":"465"},{"groupId":"BG002","value":"930"}]}],"title":"Intent to undergo PBSC transplantation: Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"394"},{"groupId":"BG001","value":"394"},{"groupId":"BG002","value":"788"}]}],"title":"Intent to undergo PBSC transplantation: No"},{"categories":[{"measurements":[{"groupId":"BG000","value":"821"},{"groupId":"BG001","value":"819"},{"groupId":"BG002","value":"1640"}]}],"title":"Anti-myeloma agent utilized/planned: Novel"},{"categories":[{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"78"}]}],"title":"Anti-myeloma agent utilized/planned: Non-novel"},{"categories":[{"measurements":[{"groupId":"BG000","value":"268"},{"groupId":"BG001","value":"263"},{"groupId":"BG002","value":"531"}]}],"title":"ISS stage at diagnosis: I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"313"},{"groupId":"BG001","value":"319"},{"groupId":"BG002","value":"632"}]}],"title":"ISS stage at diagnosis: II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"278"},{"groupId":"BG001","value":"277"},{"groupId":"BG002","value":"555"}]}],"title":"ISS stage at diagnosis: III"},{"categories":[{"measurements":[{"groupId":"BG000","value":"484"},{"groupId":"BG001","value":"481"},{"groupId":"BG002","value":"965"}]}],"title":"Previous SRE : Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"375"},{"groupId":"BG001","value":"378"},{"groupId":"BG002","value":"753"}]}],"title":"Previous SRE : No"},{"categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"42"}]}],"title":"Region: Japan"},{"categories":[{"measurements":[{"groupId":"BG000","value":"841"},{"groupId":"BG001","value":"835"},{"groupId":"BG002","value":"1676"}]}],"title":"Region: Non-Japan"}],"description":"Randomization was stratified by\n\n* Intent to undergo autologous peripheral blood stem cell (PBSC) transplantation: yes or no\n* The anti-myeloma agent being utilized/planned to be utilized in first-line therapy: novel therapy (included bortezomib, lenalidomide, or thalidomide) based or non-novel therapy-based,\n* International Staging System (ISS) stage at diagnosis: I (serum β2 microglobulin \\< 3.5 mg/L; serum albumin ≥ 3.5 g/dL) or II (neither stage I or III) or III (serum β2 microglobulin ≥ 5.5 mg/L),\n* Previous skeletal-related event (SRE): yes or no,\n* Region (Japan, non-Japan).","paramType":"NUMBER","title":"Summary of Randomization Stratifications","unitOfMeasure":"participants"}]}